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Background: Pomaglumetad methionil (LY2140023 monohydrate) is a potent and highly selective agonist for the
metabotropic glutamate mGluR2 and mGluR3 receptors. We present results of a pivotal clinical study H8Y-MC-HBBM
assessing the efficacy of LY2140023 in improving symptoms as a monotherapy in patients with an acute exacerbation
of schizophrenia.
Methods: Enrolled adult patients (ages 18? 65) with schizophrenia who had experienced an exacerbation of symptoms
within 2 weeks prior to study entry. Patients (N = 1013) were randomized 2:2:2:1 to treatment with placebo, LY40 mg
twice daily (BID), LY80 mg BID, or risperidone (RIS) 2 mg BID for 6 weeks after a one-week blinded placebo lead-in. The
primary outcome assessed change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score in an
overall schizophrenia population and a predefined subpopulation which excluded non-Hispanic white patients with
the A/A genotype at the HTR2A SNP rs7330461.
Results: Neither LY2140023 dose showed significant improvement compared to placebo on PANSS total in either
population (1-sided p-value [significance level], overall: LY40, p = .154 [0.01]; LY80, p = .698 [0.01], subpopulation: LY40,
p = .033 [0.0025]; LY80, p = .659 [0.0025], MMRM analysis). RIS statistically separated from placebo in both populations
(p < .001 [0.05]). There were no statistically significant differences in the incidence of serious adverse events, and no
seizures on LY2140023.
Conclusion: LY2140023 treatment did not demonstrate efficacy in populations studied. Overall, LY2140023 treatment
was generally well tolerated with no new adverse safety findings compared to previous trials. Further understanding of
the role of glutamate as a therapeutic target in schizophrenia is needed.
Clinical trials registration: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of
LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
ClinicalTrials.gov identifier: NCT01086748.
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Emerging evidence implicates dysregulation of the gluta-
matergic system as a key contributor to the symptoms of
schizophrenia [1-4]. The mGluR2/3 receptors function
as autoreceptors that, when stimulated by endogenous
glutamate, are able to diminish the activity of hyper-
active and dysregulated cortical pyramidal neurons [5].* Correspondence: downing_anncatherine_m@lilly.com
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unless otherwise stated.Pomaglumetad methionil (LY2140023 monohydrate,
hereafter referred to as LY2140023) is the methionine
prodrug of the potent specific mGlu2/3 receptor agonist
LY404039. It is anticipated that LY2140023 treatment
may re-establish regulated and balanced glutamatergic
cortical activity and improve psychosis.
An initial proof-of-concept study (Study HBBD) demon-
strated that patients treated with LY2140023 (40 mg twice
daily, BID) or olanzapine (15 mg) reported significant
improvement versus placebo on positive and negativel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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[6]. However, the results of a second Phase 2 study (Study
HBBI) were inconclusive. In Study HBBI, none of the
LY2140023 dose arms (5 mg, 20 mg, 40 mg, 80 mg BID),
nor the active control, olanzapine (15 mg), separated from
placebo in the treatment of acute schizophrenia. Overall,
while LY2140023 treatment was generally well-tolerated in
both studies, in the HBBI study, seizures were reported in
4 patients treated with LY2140023 [7].
The primary objective of Study HBBM tested the hy-
pothesis that LY2140023 (80 mg or 40 mg BID) would
demonstrate significantly greater efficacy than placebo fol-
lowing 6 weeks of treatment, as measured by the change
from baseline in the Positive and Negative Syndrome Scale
(PANSS) total score in an overall schizophrenia popula-
tion and/or in a predefined subpopulation which excluded
non-Hispanic white patients with the A/A genotype at
the serotonin 2A receptor (HTR2A) single nucleotide
polymorphism (SNP), rs7330461. This predefined sub-
population was defined based upon pharmacogenetic
analyses conducted from prior LY2140023 trials [8,9].




Study HBBM was a multicenter, randomized, double-
blind, parallel, fixed-dose, Phase 2 study to assess the ef-
ficacy and safety of 2 dose levels of LY2140023 (80 mg
or 40 mg BID) compared to placebo in patients with
schizophrenia, with a risperidone treatment arm to as-
sess assay sensitivity (Figure 1). The study consisted of
3 periods: a screening phase, a 7-day placebo lead-in
phase that was blinded to investigators and patients,
and a 6-week randomized treatment phase. All patients
gave written informed consent prior to entering the
study. The study protocol was approved by appropriate
institutional review boards and conducted in accord-
ance with the ethical principles stated in the Declaration
of Helsinki.
Study period I (SP I)
Eligible patients were those with an accurate and reliable
diagnosis of schizophrenia (based upon historical docu-
mentation and Structured Clinical Interview for DSM-
IV Disorders [SCID] interview), who experienced an
exacerbation of their illness 2 weeks prior to study entry
(Visit 1), leading to a need for intensification of psychi-
atric care. Patients could be antipsychotic treatment
na?ve or have had prior exposure to antipsychotic medi-
cations and were not treatment refractory in the opinion
of the investigator. Patients were excluded from study
participation if they had any other current Axis I psychi-
atric diagnoses in addition to schizophrenia, a diagnosisof substance dependence or substance abuse, a history
of one or more seizures, answered yes to any suicide-
related behaviors within 1 month of Visit 1, participated
in any clinical trial for which they received a study-
related medication in the 6 months prior to Visit 1, were
treatment refractory, or had demonstrated an inadequate
response to treatment with risperidone, or for whom
treatment with risperidone, LY2140023, or placebo was
contraindicated.
An inclusion/exclusion review process was completed
for each patient in the study prior to the patient being
entered into the blinded placebo lead-in. All patients
had to provide a blood sample for genotyping at screen-
ing to allow for appropriate classification within the pre-
defined subpopulation.
Study period II (SP II)
Patients meeting enrollment criteria continued into a
blinded (to patient and site) 7-day placebo lead-in treat-
ment phase (SP II) from Visit 2 to Visit 3. A blinded
placebo lead-in period was included in the study to im-
prove signal detection by identifying patients whose
change in PANSS total scores during this week sug-
gested a high, anomalous placebo response. Patients
were required to be hospitalized for a minimum of
3 weeks beginning at Visit 2.
Study period III (SP III)
A 6-week randomized double-blind treatment phase
from Visit 3 to Visit 9 (Week 1 ? 6) during which patients
received one of the following study drugs administered
orally BID: 40-mg LY2140023 tablets, 80-mg LY2140023
tablets, 2-mg risperidone over-encapsulated tablets, pla-
cebo tablets or capsules identical to LY2140023 and ris-
peridone. Treatment with 80 mg BID LY2140023 was
started at a dose of 40 mg BID for 3 days, followed by
an increase to the target dose of 80 mg BID. Treatment
with risperidone was started with 2 mg risperidone on
the first day, and 4 mg (2 mg given BID) each day there-
after. The 2 doses of LY2140023 were selected based on
previous clinical studies in humans. Dosing of risperi-
done was based on approved labeling.
Assessments
The primary objective of this study tested the hypothesis
that LY2140023, given orally to patients with schizo-
phrenia at 80 mg or 40 mg BID, would demonstrate sig-
nificantly greater efficacy than placebo following 6 weeks
of treatment (Visit 9), as measured by the change from
baseline in the PANSS total score [10], in one or more
of the following populations: 1) overall schizophrenia
population, 2) predefined subpopulation including all pa-
tients except non-Hispanic white patients (by self-report
of race/ethnicity) who had the A/A genotype at the
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Antipsychotic Drug Taper Double-Blind Acute Treatment
(SP I:  Up to 7 days)
Visit 1 Visit 2




(SP II: 7 days) 




Risperidone (2 mg BID)
LY2140023 (40 mg BID)
Visit 5 Visit 6 Visit 7 Visit 9






All  Patients Hospitalized
Figure 1 The unblinded study design. Study HBBM consisted of 3 periods: a screening phase, a 7-day placebo lead-in phase that was blinded
to investigators and patients, and a 6-week randomized treatment phase. All patients were hospitalized from Visits 2? 5. Patients could be
discharged after that time based upon clinical presentation.
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non-missing observation at or before Visit 3.
To help reduce potential rating bias, improve reliability,
and decrease variation, ratings were not performed by
members of the treatment team but instead by blinded, in-
dependent raters. At the majority of sites (86%), centralized
ratings via real-time video conference were conducted by
an approved vendor (MedAvante, Hamilton, USA). In
those countries where this technology was not available,
local, blinded raters who were not a part of the treatment
team performed the efficacy assessment. In both cases, the
raters were blind to the study design, entrance criteria, and
patient treatment assignment.
Key gated secondary objectives tested that LY2140023,
at 80 mg or 40 mg BID, would demonstrate significantly
greater improvement in functioning than placebo at
Visit 9 in 1) the overall schizophrenia population, and 2)
the predefined subpopulation, as assessed by the change
from baseline in the Personal and Social Performance
Scale (PSP) score [11].
Rates of discontinuation and time to discontinuation
were compared between LY2140023 and placebo. The
pharmacokinetics (PK) of LY2140023 and LY404039 were
characterized.
Safety assessments included the incidence of treatment-
emergent adverse events (TEAEs), neurological changes,
vital signs, laboratory changes, and electrocardiogram
(ECG) changes. Extrapyramidal symptoms (EPS) were
assessed by the Barnes Akathisia Scale (BAS) for akathisia
[12], Simpson-Angus Scale (SAS) for parkinsonism [13],and Abnormal Involuntary Movement Scale (AIMS) for
dyskinetic symptoms [14].
Blood samples were collected from patients for geno-
typing (Verigene? mGlu Nucleic Acid Test; Nanosphere,
Chicago, IL).
Statistical methods
It was planned to randomize approximately 880 patients
in a 2:2:2:1 ratio to LY2140023 (40 or 80 mg BID), pla-
cebo or 4 mg risperidone, respectively. This sample size
provides a greater than 94% chance of at least one sig-
nificant result from the four LY2140023 versus placebo
tests (2 populations at 2 dose levels) associated with the
primary objective. The power calculations were based on
Monte Carlo simulations assuming an effect size of 0.3
and 0.4 in the overall population and the predefined sub-
population, respectively, and the predefined subpopulation
makes up approximately 70% of the overall population.
The analyses were conducted on an intent-to-treat
(ITT) basis that included all patients according to the
treatment group to which they were assigned and received
at least 1 dose. To increase signal detection, ? placebo re-
sponders? who had a 25% or greater improvement in the
PANSS total score (based on a 1? 7 scale for each PANSS
item) during the placebo lead-in period were excluded
from the efficacy analyses. The resulting analysis popula-
tion was referred to as the efficacy-evaluable ITT patient
population.
To control the family-wise error rate associated with
testing the alternate co-primary hypotheses, a fallback
Downing et al. BMC Psychiatry 2014, 14:351 Page 4 of 12
http://www.biomedcentral.com/1471-244X/14/351testing procedure [15] was employed. This procedure
began by testing the efficacy of LY2140023 80 mg BID
treatment first in the overall population, followed by
testing the efficacy of LY2140023 40 mg BID treatment,
and then conducting the corresponding tests in the pre-
defined subpopulation [16].
For analysis of the PANSS total score in the overall
population, the mixed model repeated measure (MMRM)
included the fixed effects of treatment, pooled investiga-
tive site, visit, treatment-visit interaction, gender, prede-
fined subpopulation (yes/no) as well as the continuous,
fixed covariates of baseline score and baseline score-by-
visit interaction. In the predefined subpopulation analysis,
the categorical term of predefined subpopulation was
excluded from the model. The within-patient errors
were modeled using an unstructured covariance matrix.
The Kenward-Roger approximation was used to estimate
denominator degrees of freedom. The primary contrasts
were the LY2140023 doses versus placebo comparisons at
Visit 9.
The gated secondary outcome was change from base-
line in the PSP score. Only when the null hypotheses
from the primary testing sequence were rejected, would
testing of the gated secondary hypotheses have com-
menced using a parametric gatekeeping procedure: test
the efficacy of LY2140023 treatment versus placebo in
the overall population, followed by testing in the prede-
fined subpopulation.
The comparison between risperidone and placebo at
Visit 9 was conducted at a 2-sided alpha level of 0.05
without adjustment for multiplicity.
Time to discontinuation due to adverse events (AEs),
lack of efficacy, and for any reason were analyzed separ-
ately using Kaplan-Meier estimated survival curves; and
the log-rank test was used to do comparisons.
The safety measures, including EPS scores, vital signs,
body weight, body mass index (BMI), waist circumfer-
ence, and ECG intervals, were analyzed using the
MMRM analyses as specified previously. All the safety
analyses were based on the ITT patients in the overall
population. All tests of safety parameters were con-
ducted at a 2-sided alpha level of 0.05 without adjust-
ments for multiple comparisons.
For all other continuous variables such as patient ? s age,
height, baseline weight, BMI, waist circumference, base-
line efficacy, and baseline EPS measures, a single-factor
analysis of variance (ANOVA) with a fixed effect of
treatment was used. For changes from baseline to last
observed measure in laboratory analytes, the rank-
transformed change from baseline data were used.
For all categorical data including patient ? s gender, race,
patient disposition, TEAEs, treatment-emergent abnor-
mal, high, or low laboratory values, treatment-emergent
EPS symptoms, Fisher ? s exact test was used.Results
Baseline and demographic characteristics
Among ITT patients in the overall population, there
were no statistically significant imbalances among treat-
ment groups with respect to baseline characteristics,
psychopathology, or psychiatric history (Table 1). The
overall population was comprised of 64.1% male and
35.9% female patients, with a mean age of 40.0 years.
The mean duration of lifetime illness was 14.9 years, and
the mean number of previous psychiatric hospitaliza-
tions was 7.8. Baseline EPS was similar across the treat-
ment groups on the SAS total score and the BAS global
score, although patients randomized to LY2140023 80-
mg BID group had a higher baseline mean score on the
AIMS total score than patients in the other treatment
groups (p = .027).
Among efficacy-evaluable ITT patients in the overall
population, the mean PANSS total score at baseline was
84.1 (SD = 14.7) (Table 1).
Patient disposition
Of the 1571 patients who entered the study, 1134 patients
entered the placebo lead-in period, 1013 were randomly
assigned to treatment, 1009 received at least 1 dose of
blinded study drug, 539 completed the study (Figure 2).
Among all randomized patients, 90.7% (n = 919) were
efficacy-evaluable ITT patients, 70.5% (n = 714) were ITT
patients in the predefined subpopulation, and 64.5% (n =
653) were efficacy-evaluable ITT patients in the prede-
fined subpopulation (Table 2).
Among ITT patients in the overall population, the rate
of study completion was significantly higher in the pla-
cebo group (58%) than in the LY2140023 40-mg BID
(49.0%; p = .032) and 80-mg BID (46.1%; p = .005) groups
(Table 3). The most common reasons for early discon-
tinuation were perceived lack of efficacy ? physician deci-
sion (159 patients, 15.8%), subject decision ? consent
withdrawn (107 patients, 10.6%), and AEs? physician de-
cision (81 patients, 8.0%). The incidence of discontinu-
ation due to perceived lack of efficacy-physician decision
was significantly higher than placebo in the LY2140023
80-mg BID group (p = .025) and significantly lower than
placebo in the risperidone group (p = .007). No other
statistically significant differences were found.
There was a statistically significant overall difference
among all treatment groups in time to discontinuation for
any reason (p < .001) (Figure 3) and time to discontinu-
ation due to lack of efficacy (p < .001) (data not shown).
Compared to placebo, patients in the LY2140023 groups
had a significantly shorter time to study discontinuation
for any reason (LY2140023 40-mg BID group, p = .036;
80-mg BID group, p = .003) and a significantly shorter
time to discontinuation due to lack of efficacy (LY2140023
40-mg BID group, p = .020; 80-mg BID group, p = .006).
Table 1 Summary of patient baseline characteristics
Characteristics PBO LY40 LY80 RIS TOTAL Overall p-Value
ITT Overall Population N = 295 N = 292 N = 280 N = 142 N = 1009
Age, years, mean (SD) 39.8 (11.4) 39.6 (11.5) 40.5 (11.5) 40.3 (11.1) 40.0 (11.5) 0.771
Gender, male, n (%) 181 (61.4) 196 (67.1) 183 (65.4) 87 (61.3) 647 (64.1) 0.422
Ethnicity, n (%) 0.612
Hispanic or Latino 13 (4.4) 11 (3.8) 15 (5.4) 9 (6.3) 48 (4.8)
Not Hispanic or Latino 282 (95.6) 281 (96.2) 265 (94.6) 133 (93.7) 961 (95.2)
Race, n (%) 0.899
American Indian or Alaska Native 1 (0.3) 0 (0.0) 1 (0.4) 0 (0.0) 2 (0.2)
Asian 1 (0.3) 2 (0.7) 1 (0.4) 0 (0.0) 4 (0.4)
Black or African American 102 (34.6) 100 (34.2) 94 (33.6) 47 (33.1) 343 (34.0)
Multiple 6 (2.0) 1 (0.3) 6 (2.1) 1 (0.7) 14 (1.4)
Native Hawaiian or Other Pacific Islander 2 (0.7) 1 (0.3) 1 (0.4) 1 (0.7) 5 (0.5)
White 183 (62.0) 188 (64.4) 177 (63.2) 93 (65.5) 641 (63.6)
Weight (kg), mean (SD) 81.4 (20.8) 81.4 (20.4) 83.3 (19.2) 82.7 (21.9) 82.1 (20.4) 0.622
Duration of Lifetime Illness , years, mean (SD) 14.5 (10.7) 14.6 (10.7) 15.6 (11.0) 15.2 (10.4) 14.9 (10.7) 0.607
Number of Past Psychiatric Hospitalizations, mean (SD) 8.0 (9.4) 7.2 (7.3) 8.2 (8.8) 7.4 (5.7) 7.8 (8.2) 0.439
Simpson-Angus Total Score, mean (SD) 0.5 (1.4) 0.4 (1.2) 0.5 (1.9) 0.6 (1.7) 1.5 (1.5) 0.718
Barnes Akathisia Global Score, mean (SD) 0.1 (0.5) 0.1 (0.5) 0.1 (0.4) 0.1 (0.4) 0.1 (0.5) 0.799
AIMS 1? 7 Total Score, mean (SD) 0.4 (1.2) 0.2 (1.1) 0.6 (2.0) 0.2 (1.0) 0.4 (1.4) 0.027
Efficacy-Evaluable ITT Population N = 267 N = 267 N = 253 N = 132 N = 919
PANSS Total Score, mean (SD) 84.3 (14.8) 83.7 (14.0) 84.2 (14.5) 84.0 (16.2) 84.1 (14.7) 0.971
Abbreviations: AIMS Abnormal Involuntary Movement Scale, ITT intent-to-treat, kg kilogram, n/N number of patients, PANSS Positive and Negative Syndrome Scale,
SD standard deviation.
Groups: PBO = placebo; LY40 = LY2140023 monohydrate 40 mg; LY80 = LY2140023 monohydrate 80 mg; RIS = risperidone.
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Figure 2 Patient disposition.
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Table 2 Summary of study population for all entered patients
Analysis Population PBO n (%)a LY40 n (%)a LY80 n (%)a RIS n (%)a Total n (%)a
Randomized Patients N = 295 N = 293 N = 282 N = 143 N = 1013
Completed 171 (58.0) 143 (48.8) 129 (45.7) 96 (67.1) 539 (53.2)
ITT Patients in the Overall Population 295 (100.0) 292 (99.7) 280 (99.3) 142 (99.3) 1009 (99.6)
Completed 171 (58.0) 143 (48.8) 129 (45.7) 96 (67.1) 539 (53.2)
Efficacy-Evaluable ITT Patients in the Overall Population 267 (90.5) 267 (91.1) 253 (89.7) 132 (92.3) 919 (90.7)
Completed 154 (52.2) 136 (46.4) 116 (41.1) 90 (62.9) 496 (49.0)
ITT Patients in the Predefined Subpopulation 211 (71.5) 210 (71.7) 195 (69.1) 98 (68.5) 714 (70.5)
Completed 120 (40.7) 107 (36.5) 83 (29.4) 65 (45.5) 375 (37.0)
Efficacy-Evaluable ITT Patients in the Predefined Subpopulation 195 (66.1) 189 (64.5) 176 (62.4) 93 (65.0) 653 (64.5)
Completed 111 (37.6) 101 (34.5) 73 (25.9) 61 (42.7) 346 (34.2)
aPercentages were calculated based on all randomized patients per group.
Abbreviations: ITT intent-to-treat, N/n number of patients.
Groups: PBO = placebo; LY40 = LY2140023 monohydrate 40 mg; LY80 = LY2140023 monohydrate 80 mg; RIS = risperidone.
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time to discontinuation due to lack of efficacy compared to
patients in the placebo group (p = .010). There was no sta-
tistically significant difference among all treatment groups
in the time to discontinuation due to AEs (p = .174).
Efficacy measures
Primary objective
Within-treatment-group improvement on PANSS total
score from baseline was observed for all treatment groups
at each visit for the efficacy-evaluable ITT overall popula-
tion and the efficacy-evaluable ITT predefined subpopula-
tion (Figure 4A,B). Following the testing procedure
specified for the primary outcome, neither LY2140023
dose showed a statistically significant improvement on the
PANSS total score at endpoint compared with placebo in
either population (Table 4). Risperidone statistically sepa-
rated from placebo on PANSS total score at endpoint in
both populations (p < .001).
Other efficacy measures
Since the relevant primary null hypotheses were not
rejected, no testing of the gated secondary objectives
was needed.
Sensitivity analyses
For efficacy measures, all primary and secondary analyses
were applied to the ITT overall population (included 90
placebo responders) and the ITT predefined subpopula-
tion (included 61 placebo responders) to monitor sensi-
tivity of the findings to the inclusion of placebo responders.
Inclusion of the placebo responders did not change
the results.
Pharmacokinetic analyses and results
A parent-metabolite model was developed in which
parameters for both LY2140023 and LY404039 weredetermined simultaneously. The HBBM data fit to
models developed in previous studies of LY2140023 and
was consistent with administration of oral LY2140023
(HBBM Additional file 1).
Safety measures
A total of 44 (4.4%) patients experienced at least 1 serious
adverse event (SAE) during the study. The most frequently
occurring SAEs were schizophrenia-related events (pre-
ferred term: schizophrenia, n = 19, 1.9%; psychotic dis-
order, n = 5, 0.5%). All other SAEs were reported in <1% of
patients. There were no significant between-group differ-
ences related to serious adverse events.
One patient in the LY2140023 80-mg BID group died
secondary to cocaine intoxication. Two additional deaths
occurred in patients who signed informed consent to
participate but prior to receiving randomized treatment.
One patient died of acute cardiac arrest during the
screening period, and 1 patient committed suicide dur-
ing the placebo lead-in period.
To ensure all potential seizure cases were appropriately
confirmed as events, an external seizure adjudication com-
mittee was employed. Four cases were adjudicated with 3
being confirmed as seizures. Two patients experienced a
seizure prior to randomization to study treatment. One
patient who experienced a seizure was randomized to
treatment with risperidone. No seizures occurred in pa-
tients taking LY2140023.
The overall incidence of AEs leading to study discon-
tinuation was not significantly different between treatment
groups (p = .208). Overall, 104 (10.3%) patients discontin-
ued due to AEs. The percentage of patients who discontin-
ued the study due to AEs were as follows: placebo, 11.2%;
LY40, 7.9%; LY80, 12.9%; and risperidone, 8.5%. The most
frequently reported AE leading to discontinuation in all
treatment groups was schizophrenia (placebo, 4.4%; LY40,
2.7%; LY80, 4.3%;risperidone, 2.8%), followed by psychotic
Table 3 Reasons for study discontinuation for all ITT patients in the overall population
p-value








Completed 171 (58.0) 143 (49.0) 129 (46.1) 96 (67.6) 539 (53.4) <.001 0.032 0.005 0.059
Discontinued
Adverse Event-Physician Decision 24 (8.1) 18 (6.2) 29 (10.4) 10 (7.0) 81 (8.0) 0.322 0.424 0.389 0.849
Adverse Event-Subject Decision 9 (3.1) 6 (2.1) 7 (2.5) 2 (1.4) 24 (2.4) 0.770 0.603 0.802 0.515
Entry Criteria Not Met 1 (0.3) 1 (0.3) 0 (0.0) 0 (0.0) 2 (0.2) >.999 >.999 >.999 >.999
Lost to follow up 9 (3.1) 4 (1.4) 6 (2.1) 3 (2.1) 22 (2.2) 0.576 0.262 0.604 0.759
Perceived Lack of Efficacy-Physician Decision 39 (13.2) 56 (19.2) 57 (20.4) 7 (4.9) 159 (15.8) <.001 0.057 0.025 0.007
Perceived Lack of Efficacy-Subject Decision 9 (3.1) 14 (4.8) 12 (4.3) 3 (2.1) 38 (3.8) 0.499 0.296 0.508 0.759
Protocol Violation 5 (1.7) 10 (3.4) 7 (2.5) 3 (2.1) 25 (2.5) 0.616 0.202 0.568 0.718
Scheduling Conflict 1 (0.3) 1 (0.3) 0 (0.0) 0(0.0) 2 (0.2) >.999 >.999 >.999 >.999
Sponsor Decision 1 (0.3) 1 (0.3) 1 (0.4) 0 (0.0) 3 (0.3) >.999 >.999 >.999 >.999
Subject Decision-Consent Withdrawn 26 (8.8) 33 (11.3) 30 (10.7) 18 (12.7) 107 (10.6) 0.596 0.339 0.483 0.235
Subject is Moving or
has Moved
0 (0.0) 4 (1.4) 1 (0.4) 0 (0.0) 5 (0.5) 0.082 0.061 0.487
Transportation Issues 0 (0.0) 1 (0.3) 1 (0.4) 0 (0.0) 2 (0.2) 0.668 0.497 0.487
Abbreviations: ITT intent-to-treat, N/n number of patients.
Groups: PBO = placebo; LY40 = LY2140023 monohydrate 40 mg; LY80 = LY2140023 monohydrate 80 mg; RIS = risperidone.



















Figure 3 Kaplan-Meier time to discontinuation for any reason; intent-to-treat patients in the overall population.
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peridone, 0%). All other AEs leading to discontinuation
occurred in <1% of patients overall.
As indicated in Table 5, there was a statistically signifi-
cant overall difference observed among treatment
groups in weight increase (with risperidone > placebo),
restlessness, extrapyramidal disorder, dysmenorrhoea
(with LY40 > placebo), sinusitis (with LY40 > placebo),
asthenia, fatigue, and hyperhidrosis across all treatment
groups.
Analysis of change from baseline to endpoint in la-
boratory tests showed statistically significant changes
within groups and when compared with placebo, al-
though the majority of the changes are not viewed
as clinically relevant. Mean eosinophil increases were
statistically significant for both LY2140023 treatment
groups in the overall comparison and pairwise versus
placebo. At Visit 9, a statistically significant increase was
seen for LY2140023 80-mg BID group. In the treatment-
emergent abnormal analysis, both LY2140023 treatment
groups showed a statistically significant increase in the
number of patients displaying a high eosinophil count
overall and versus placebo. However, no clinical corre-
lates were noted with the eosinophil increases. Statisti-
cally significant increases in prolactin were noted for
both LY2140023 80-mg BID (mean change, 1.16 μg/L)
and risperidone (mean change, 50.90 μg/L) groups.
Statistically significant increases from baseline were
seen on fasting glucose levels for patients treated with
risperidone (p < 0.001) and placebo (p = 0.010). No sta-
tistically significant changes versus placebo in total chol-
esterol, HDL, LDL, or triglycerides were seen in the
mean change laboratory reports. However, statisticallysignificant reductions in total cholesterol from baseline
were seen for both LY2140023 40 mg (p = .002) and
LY2140023 80 mg (p < .001) treatment groups. Statisti-
cally significant reductions from baseline were also seen
in triglycerides for LY2140023 80 mg treatment group
(p = .028). All treatment arms showed statistically signifi-
cant reductions in LDL cholesterol (placebo, p < .001;
LY40, p = .018; LY80, p < .01; risperidone, p = .022); while
no clinically relevant changes in HDL were noted across
any of the treatment arms.
Overall, a significant difference was observed among
treatment groups for potentially clinically significant (PCS)
weight increases (p < .001), but not for PCS weight loss
(p = .097). Compared with placebo, the risperidone group
showed a PCS weight increase (14.6% of patients, p < .001)
in the overall population. No significant differences were
observed between placebo and either LY2140023 treatment
group.
There were no clinically significant findings on vital
signs or ECGs for patients treated with LY2140023 com-
pared to placebo.
Extrapyramidal symptoms
On the AIMS total score, the LY2140023 80-mg BID
group had a statistically significant decrease compared
to placebo at Visit 9 (MMRM analysis of change from
baseline, p = .049). There were no statistically significant
differences from placebo in any of the treatment groups
for the BAS global score or SAS total score. There were
no statistically significant differences from placebo in
categorical analysis of treatment-emergent akathisia,
parkinsonism, or dyskinesia in any of the treatment
groups.
Figure 4 Plot of weekly least-squares mean (+/−standard error [SE]) of efficacy measures by treatment. Repeated measures analysis of
change from baseline to each postbaseline visit (MMRM), efficacy-evaluable intent-to-treat patients in the overall population (A) and in the
predefined subpopulation (B). In the figures, Week 0 corresponds to study Visit 3, and Week 6 corresponds to study Visit 9.
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There were no statistically significant differences between
groups in the concomitant use of benzodiazepines/hyp-
notics/anxiolytics, anticholinergics, psychotropics, (antide-
pressants, mood stabilizers, and antipsychotics), antidiabetic
and lipid/cholesterol lowering agents, or any other classes
of medications during the study.
Discussion
Study HBBM was a multicenter, randomized, double-
blind, placebo- and comparator-controlled, parallel,
fixed-dose, Phase 2 study conducted to assess the effi-
cacy and safety of 2 dose levels of LY2140023 (80 mg
BID or 40 mg BID) in patients with schizophrenia over
6 weeks of randomized treatment. Two populations,
both the overall schizophrenia population and a prede-
fined subpopulation of patients defined by genotype of
the HTR2A SNP, rs7330461, race, and ethnicity, were
evaluated as a part of the primary objective. LY2140023
did not separate from placebo in the primary efficacyendpoint (i.e., change in PANSS total score) in either the
overall or predefined subpopulation at the 2 doses inves-
tigated (40 mg and 80 mg BID). The active control, ris-
peridone, did separate from placebo in both populations.
Therefore, HBBM is a negative study.
In an earlier clinical trial (Study HBBI), none of the
LY2140023 dose arms (5 mg, 20 mg, 40 mg, 80 mg
BID), nor the active control, olanzapine (15 mg), sepa-
rated from placebo in the treatment of acute schizophre-
nia symptoms likely due to a higher than expected
placebo response (−14.6 points) [7]. Research has
highlighted an increasing placebo response in schizo-
phrenia clinical trials [17], and enrichment designs have
been developed to separate early placebo responders
from randomized patients [18]. This study utilized sev-
eral methods to attempt to prevent an abnormal placebo
response, including the use of blinded independent
raters and a 1-week placebo lead-in phase to identify
? placebo responders ? who were excluded from the pri-
mary efficacy analysis. The resulting mean PANSS total
Table 4 Primary analysis mixed-model repeated measures at visit 9 ? PANSS total score in efficacy-evaluable ITT
patients






Overall population PBO 253 −7.9
RIS 124 −16.6 −8.7 [<.001]* 0.05* Validity: S
LY80 229 −7.1 0.8 [0.698] 0.01 Step 1: NS
LY40 251 −9.4 −1.5 [0.154] 0.01 Step 2: NS
Predefined subpopulation PBO 184 −7.2
RIS 87 −16.3 −9.1 [<.001]* 0.05* Validity: S
LY80 160 −6.4 0.8 [0.659] 0.0025 Step 1: NS
LY40 178 −10.5 −3.3 [0.033] 0.0025 Step 2: NS
Abbreviations: ITT intent-to-treat, LSMean least-squares mean, NS not significant, PANSS Positive and Negative Syndrome Scale, S significant.
Groups: PBO = placebo; LY40 = LY2140023 monohydrate 40 mg; LY80 = LY2140023 monohydrate 80 mg; RIS = risperidone.
*For the risperidone group, the 2-sided p-value and significance level were used.
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was not found to be excessive and was consistent with
similar conclusive antipsychotic drug efficacy clinical tri-
als reported in the literature [19,20]. However, despite
the utilization of those methods to improve signal detec-
tion, LY2140023 did not show greater improvementTable 5 Treatment-emergent adverse events preferred term b
significant comparison level ITT patients in the overall popul
Preferred term PBO N = 295
n (%)
LY40 N = 292
n (%)
LY80 N = 280
n (%)
Patients with > = 1 TEAE 177 (60.0) 159 (54.5) 176 (62.9)
Headache 27 (9.2) 20 (6.8) 21 (7.5)
Schizophrenia 23 (7.8) 14 (4.8) 16 (5.7)
Nausea 14 (4.7) 22 (7.5) 16 (5.7)
Insomnia 21 (7.1) 10 (3.4) 15 (5.4)
Blood CK increased 15 (5.1) 12 (4.1) 17 (6.1)
Anxiety 9 (3.1) 11 (3.8) 12 (4.3)
Vomiting 6 (2.0) 11 (3.8) 13 (4.6)
Dyspepsia 5 (1.7) 7 (2.4) 11 (3.9)
Constipation 8 (2.7) 7 (2.4) 7 (2.5)
Psychotic disorder 7 (2.4) 6 (2.1) 10 (3.6)
Agitation 3 (1.0) 8 (2.7) 10 (3.6)
Weight increased 2 (0.7) 4 (1.4) 1 (0.4)
Restlessness 5 (1.7) 1 (0.3) 0 (0.0)
Extrapyramidal disorder 3 (1.0) 0 (0.0) 6 (2.1)
Dysmenorrhoea 0 (0.0 5 (5.2) 0 (0.0)
Sinusitis 0 (0.0) 5 (1.7) 0 (0.0)
Asthenia 2 (0.7) 0 (0.0) 0 (0.0)
Fatigue 1 (0.3) 0 (0.0) 1 (0.4)
Hyperhidrosis 0 (0.0) 0 (0.0) 1 (0.4)
Abbreviations: CK creatine phosphokinase, ITT intent-to-treat, N/n number of patients
Groups: PBO = placebo; LY40 = LY2140023 monohydrate 40 mg; LY80 = LY2140023
Note: p-values are calculated from Fisher's exact test; * indicates nominal 2-sided pcompared to placebo. Furthermore, sensitivity analyses
that included the placebo responders did not signifi-
cantly alter treatment outcome. Therefore, the trial was
conclusive in not showing antipsychotic efficacy for
LY2140023 in the populations studied. In addition, an-
other clinical trial (Study HBBN) with a similar studyy decreasing frequency ≥ 2% of patients or statistically
ation
p-value
RIS N = 142
n (%)








82 (57.7) 594 (58.9) 0.220 0.183 0.494 0.678
11 (7.7) 79 (7.8) 0.770 0.362 0.547 0.719
5 (3.5) 58 (5.7) 0.284 0.174 0.407 0.098
5 (3.5) 57 (5.6) 0.338 0.172 0.708 0.627
10 (7.0) 56 (5.6) 0.188 0.064 0.396 >.999
4 (2.8) 48 (4.8) 0.485 0.694 0.717 0.327
5 (3.5) 37 (3.7) 0.887 0.657 0.508 0.778
5 (3.5) 35 (3.5) 0.350 0.229 0.102 0.347
8 (5.6) 31 (3.1) 0.105 0.575 0.130 0.033*
5 (3.5) 27 (2.7) 0.900 >.999 >.999 0.765
2 (1.4) 25 (2.5) 0.594 >.999 0.465 0.724
1 (0.7) 22 (2.2) 0.102 0.141 0.050* >.999
5 (3.5) 12 (1.2) 0.049* 0.449 >.999 0.039*
4 (2.8) 10 (1.0) 0.008* 0.216 0.062 0.481
0 (0.0) 9 (0.9) 0.029* 0.249 0.329 0.554
1 (1.8) 6 (1.7) 0.006* 0.019* 0.325
1 (0.7) 6 (0.6) 0.013* 0.030* 0.325
4 (2.8) 6 (0.6) 0.002* 0.499 0.499 0.091
3 (2.1) 5 (0.5) 0.031* >.999 >.999 0.103
2 (1.4) 3 (0.3) 0.019* 0.487 0.105
, TEAE treatment-emergent adverse event.
monohydrate 80 mg; RIS = risperidone.
-value < = 0.05.
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stopped for futility based upon an interim analysis (early
termination; NCT01307800).
The time to all-cause discontinuation was shorter on
both doses of LY2140023 than on placebo. While time
to discontinuation due to AEs was comparable between
the LY2140023 and placebo treatment groups, time to
discontinuation due to lack of efficacy was shorter on
both doses on LY2140023 than on placebo. The reasons
why patients discontinued sooner on either dose of
LY2140023 compared to placebo are unclear, although
? Perceived Lack of Efficacy-Physician Decision ? re-
ported as a reason for early study discontinuation dif-
fered significantly among groups (LY2140023 80-mg
BID group > placebo). Patients in the risperidone group
had a significantly longer time to discontinuation due to
lack of efficacy compared to those treated with placebo.
Both LY2140023 doses were found to be generally
safe and well tolerated. The most common TEAEs were
headache, schizophrenia-related events, nausea, insom-
nia, and increased blood CK, and these observed TEAEs
are generally consistent with those reported in previous
trials [7,21]. The TEAEs seen in patients treated with
risperidone were consistent with the known AE profile
of this antipsychotic. While significant differences be-
tween treatment groups and placebo were observed in
laboratory analytes and vital signs, those differences
were generally small and not considered to be clinically
relevant. Although the AE of extrapyramidal disorders
was significantly associated with 80 mg LY2140023,
this event was not reflected in rating scales. LY2140023
was not associated with weight changes compared to
placebo.
Three patients experienced a seizure during the study,
although none occurred in either LY2140023 dose
group. The aggregate data as of June 2012 provides
crude and exposure-adjusted incidence rates which are
comparable to the rates of atypical antipsychotics [22].
The crude incidence rate was calculated to be 0.264%
and an exposure adjusted incidence (per patient year) of
0.011 (Lilly data on file).
The increase in prolactin levels due to treatment with
risperidone (+50.90 ug/L) was anticipated and is consist-
ent with the reported literature. The statistically signifi-
cant increase in mean serum prolactin with LY2140023
80 mg BID (+1.16 ug/L) has not been seen previously,
although the magnitude of this increase is small and
may reflect normal variance, and its significance relative
to placebo may have been influenced by the decrease in
mean prolactin with placebo treatment.
Limitations
Selecting Visit 3 for baseline due to the blinded placebo
lead-in design may have resulted in a baseline PANSStotal score that does not fully represent the acute state
of illness of patients at Visit 1. The placebo lead-in may
have led to the discontinuation of otherwise appropriate
patients to have studied in this trial and lessened the re-
sponse to treatment on efficacy scales. The high discon-
tinuation rate on LY2140023 represents a significant
number of missing patients whose potential data could
have informed the final results differently (eg, better un-
derstanding of who are the patients who cannot tolerate
LY2140023).Conclusion
Treatment with LY2140023 at the studied doses was not
efficacious in improving symptoms of an acute exacerba-
tion of illness in patients suffering from schizophrenia as
studied in this trial. Overall, LY2140023 was generally
well tolerated with no new significant adverse safety
findings compared to previous trials. Further under-
standing of the role of glutamate as a therapeutic target
in schizophrenia is needed.Additional file
Additional file 1: Plasma LY2140023 and LY404039 concentrations
versus time.
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